United States Drug Patent 8,324,242: Scope, Claims, Expiration, Orange Book Status, and Competitive Landscape
U.S. Patent No. 8,324,242 protects the use of ivacaftor, marketed as Kalydeco, to treat cystic fibrosis, with dependent claims directed specifically to patients carrying the G551D CFTR mutation. The patent is assigned to Vertex Pharmaceuticals Incorporated and has a listed expiration date of May 24, 2027. Its principal commercial value is as a method-of-use patent covering the original G551D indication rather than as a composition-of-matter patent.
What drug does U.S. Patent 8,324,242 cover?
The active compound named in claim 1 is ivacaftor, chemically identified as N-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide. Ivacaftor is a CFTR potentiator that increases chloride transport through defective or low-activity CFTR channels.
| Item |
Information |
| Patent |
U.S. Patent No. 8,324,242 |
| Title |
Methods of treating cystic fibrosis |
| Patent holder |
Vertex Pharmaceuticals Incorporated |
| Active ingredient |
Ivacaftor, VX-770 |
| Brand |
Kalydeco |
| Therapeutic class |
CFTR potentiator |
| Patent type |
Method of treatment |
| Priority date |
May 24, 2007 |
| Filing date |
May 23, 2008 |
| Issue date |
December 4, 2012 |
| Listed expiration |
May 24, 2027 |
| Primary mutation in claims |
G551D CFTR |
| FDA product |
Kalydeco tablets, oral granules, and oral solution-related presentations |
The patent does not claim ivacaftor as a chemical compound. Earlier Vertex patent families cover the compound and related pharmaceutical compositions. U.S. Patent 8,324,242 instead claims administering an effective amount of ivacaftor to a patient with cystic fibrosis.[1]
What do the claims of U.S. Patent 8,324,242 require?
Claim 1: Broad cystic fibrosis treatment method
Claim 1 covers:
- A patient with cystic fibrosis;
- Administration of an effective amount of ivacaftor; and
- Treatment or reduction in the severity of cystic fibrosis.
The claim does not expressly limit the patient to G551D, a particular age, dosage, formulation, route of administration, or disease stage. On its face, claim 1 is broader than the dependent claims because it applies to cystic fibrosis patients generally.
The principal limitations are therapeutic:
- The patient must have cystic fibrosis.
- Ivacaftor must be administered.
- The amount must be effective.
- The administration must treat or lessen disease severity.
The claim is not directed to merely prescribing, selling, or manufacturing ivacaftor. It is directed to the act of administering the drug for the claimed therapeutic purpose.
Claim 2: G551D mutation limitation
Claim 2 depends on claim 1 and requires that the patient possess a CFTR with a G551D mutation. This narrows claim 1 to a genetically defined cystic fibrosis population.
G551D is a gating mutation. CFTR protein reaches the cell surface but has impaired channel opening. Ivacaftor was developed to improve channel opening in this class of CFTR defect.
Claim 2 does not expressly require that G551D be present on both alleles. It therefore encompasses patients with at least one G551D mutation, subject to the ordinary interpretation of the claim language and the patent's specification.
Claim 3: Homozygous G551D patients
Claim 3 further limits claim 2 to patients who are homozygous for G551D. The patient has G551D mutations on both CFTR alleles.
This is a narrower claim than claim 2. An accused use involving a patient with two G551D alleles would fall within the literal genetic limitation of claim 3 if the other claim requirements are met.
Claim 4: Heterozygous G551D patients
Claim 4 further limits claim 2 to patients who are heterozygous for G551D. The patient has one G551D allele and a different CFTR allele.
Claim 4 is commercially important because many cystic fibrosis patients with G551D are compound heterozygotes rather than homozygotes. The claim prevents a potential design-around based solely on treating patients who carry G551D on one allele.
How broad is the patent scope?
The patent has a layered scope:
| Claim |
Patient population |
Relative scope |
| 1 |
Cystic fibrosis patients generally |
Broadest claim |
| 2 |
Cystic fibrosis patients with at least one G551D mutation |
Narrower |
| 3 |
G551D/G551D homozygous patients |
Narrowest genotype-specific claim |
| 4 |
G551D heterozygous patients |
Narrow genotype-specific claim |
Claim 1 creates the broadest asserted method-of-treatment position. Claims 2 through 4 provide mutation-specific fallback positions. If claim 1 were narrowed or invalidated, the dependent claims could continue to protect the G551D population if they satisfy validity requirements.
The patent does not expressly require:
- A particular ivacaftor dose;
- Twice-daily administration;
- Oral administration;
- Tablet, granule, or liquid dosage form;
- Treatment of pulmonary exacerbations;
- A minimum improvement in lung function;
- A specific age group;
- Combination treatment with a CFTR corrector;
- A particular duration of therapy.
Those limitations may appear in the specification, clinical data, FDA labeling, or separate patents, but they are not express limitations of the four claims provided.
What formulations are protected by U.S. Patent 8,324,242?
The patent claims the therapeutic use of ivacaftor, not a specific formulation. A tablet, oral granule, oral solution, or other dosage form could potentially satisfy the claims if it is used to administer an effective amount of ivacaftor to a covered patient.
Separate formulation patents may provide additional protection for:
- Immediate-release tablets;
- Oral granules;
- Pediatric dosage forms;
- Taste-masked formulations;
- Solubilized or bioavailability-enhanced compositions;
- Fixed-dose combinations containing ivacaftor and a CFTR corrector.
This distinction matters because a generic manufacturer could avoid a formulation patent while still facing the method-of-use claims of U.S. Patent 8,324,242. Conversely, a manufacturer could challenge the method patent while accepting separate formulation restrictions.
What is the Orange Book status of U.S. Patent 8,324,242?
U.S. Patent 8,324,242 is listed in the FDA Orange Book for Kalydeco as a method-of-use patent. Its commercial relevance comes from the use code associated with treatment of cystic fibrosis, particularly the G551D mutation population.[2]
An Orange Book listing can require an ANDA applicant to address the patent through one of four certifications:
- Paragraph I: No patent information has been submitted.
- Paragraph II: The patent has expired.
- Paragraph III: The applicant will not market until patent expiration.
- Paragraph IV: The patent is invalid, unenforceable, or will not be infringed.
For a listed method-of-use patent, an ANDA applicant can also seek approval with a section viii statement that omits the patented indication. The viability of that approach depends on whether the remaining label still encourages or necessarily involves the patented use.
When does U.S. Patent 8,324,242 expire?
The listed expiration date is May 24, 2027. That date reflects the patent term associated with the May 24, 2007 priority filing.
| Milestone |
Date |
| Priority filing |
May 24, 2007 |
| U.S. filing |
May 23, 2008 |
| Patent issued |
December 4, 2012 |
| Listed expiration |
May 24, 2027 |
| Potential generic entry under ordinary patent timing |
May 25, 2027, absent earlier resolution |
The expiration date should be distinguished from regulatory exclusivity. Kalydeco received FDA approval in January 2012 for patients aged six and older with the G551D mutation. FDA exclusivity periods ran separately from the patent term and did not extend the patent's basic expiration date.[3]
What was the FDA regulatory history for Kalydeco?
The FDA approved Kalydeco on January 31, 2012, as the first drug directed at the underlying CFTR defect rather than only treating downstream cystic fibrosis symptoms.[3] The original approval covered patients with the G551D mutation.
Subsequent regulatory expansion included:
- Younger pediatric patients;
- Additional CFTR gating mutations;
- The R117H mutation;
- Oral granule and other pediatric presentations;
- Combination regimens with CFTR correctors in broader mutation populations.
The original U.S. Patent 8,324,242 claims are narrower than the current commercial scope of all ivacaftor-containing products. Later indications, combinations, and formulations may be protected by separate patent families.
How does this patent compare with the ivacaftor composition patent?
The composition-of-matter patent and U.S. Patent 8,324,242 occupy different positions in the patent estate.
| Issue |
Composition patent |
U.S. Patent 8,324,242 |
| Protected subject matter |
Ivacaftor molecule and related compounds |
Administration of ivacaftor to treat cystic fibrosis |
| Primary risk |
Manufacturing, selling, or using the compound |
Using ivacaftor for the claimed treatment |
| Patient genotype required |
Generally no |
G551D only in dependent claims |
| Formulation limitation |
May cover compositions or dosage forms |
None expressly stated |
| Commercial role |
Core molecule protection |
Indication and patient-population protection |
| Typical generic strategy |
Challenge compound validity or wait for expiration |
Section viii carveout, Paragraph IV, or label restriction |
An expired or expiring composition patent does not automatically eliminate infringement risk under an unexpired method-of-use patent. The reverse is also true: a method patent does not replace composition protection for the molecule.
What patent landscape surrounds Kalydeco and ivacaftor?
The ivacaftor landscape includes several patent categories.
Compound patents
These cover ivacaftor and chemically related CFTR potentiators. Their importance is highest during the period when the active ingredient itself remains protected.
Method-of-use patents
These cover treatment of cystic fibrosis patients with particular mutations, including G551D and other gating defects. U.S. Patent 8,324,242 is in this category.
Formulation patents
These cover oral dosage forms, pediatric formulations, granules, liquid preparations, and pharmaceutical compositions designed to deliver ivacaftor.
Combination-product patents
Ivacaftor is used in combination products such as:
- Ivacaftor/lumacaftor;
- Ivacaftor/tezacaftor;
- Ivacaftor/elexacaftor/tezacaftor.
These products have separate patents covering the corrector compounds, combinations, formulations, dosing regimens, and treatment populations.
Manufacturing patents
Manufacturing claims may cover synthetic intermediates, crystallization, purification, polymorphs, and processes for producing ivacaftor or combination-product ingredients. These claims can create supply-chain barriers even after a core compound patent expires.
Which companies are challenging Kalydeco exclusivity?
No major public final judgment or settlement specific to U.S. Patent 8,324,242 establishes that the patent is invalid or unenforceable. The principal competitive threat is an ANDA applicant seeking approval after the patent expiry date or attempting a Paragraph IV challenge.
Potential entry pathways include:
- Waiting for the May 2027 patent expiration;
- Filing a Paragraph IV certification;
- Filing a section viii statement that removes the G551D indication;
- Developing an alternative ivacaftor formulation that does not practice a separately protected formulation claim;
- Challenging the patent's written description, enablement, anticipation, obviousness, or claim construction.
A section viii strategy may be difficult if the remaining generic label still recommends ivacaftor for cystic fibrosis patients in a manner that necessarily includes G551D patients. The FDA label and prescribing information must be reviewed together with the proposed generic labeling.
What Paragraph IV risks apply to this patent?
A Paragraph IV challenge could target several legal issues.
Written description and enablement
The challenger could argue that the broad treatment claim lacks adequate support across all cystic fibrosis patients, particularly if the specification's experimental evidence is concentrated on G551D or a limited group of mutations.
Obviousness
A challenger could combine prior art relating to:
- CFTR channel biology;
- Gating mutations;
- Small-molecule CFTR potentiators;
- Ivacaftor's pharmacology;
- Clinical treatment of cystic fibrosis.
The patent holder would rely on the compound's clinical efficacy, mutation-specific response, and the technical difficulty of predicting which CFTR mutations would respond.
Claim construction
Disputes could concern:
- The meaning of "effective amount";
- The scope of "treating or lessening the severity";
- Whether claim 1 covers every cystic fibrosis genotype;
- Whether a patient must have a demonstrable G551D mutation to practice claim 1;
- Whether a product label induces the claimed administration.
Induced infringement
A generic applicant may face induced-infringement allegations if its labeling instructs physicians to use ivacaftor for a patented population. A carveout must remove the patented use without leaving promotional or labeling language that encourages that use.
How strong is the patent estate for ivacaftor?
U.S. Patent 8,324,242 is commercially meaningful but narrower than a live composition patent. Its strengths are:
- Clear identification of ivacaftor;
- A defined therapeutic use;
- Specific dependent claims for homozygous and heterozygous G551D patients;
- Orange Book listing;
- Direct connection to the original FDA-approved Kalydeco indication.
Its limitations are:
- It is a method patent rather than a molecule patent;
- Claim 1 may face breadth challenges;
- The dependent claims are limited to G551D;
- It does not expressly protect formulations or combination products;
- The patent expires in 2027;
- Generic applicants may attempt a label carveout.
The broader Vertex franchise has stronger commercial protection where separate patents cover combination products and newer CFTR modulator regimens. U.S. Patent 8,324,242 should therefore be analyzed as one layer of the ivacaftor estate, not as the sole barrier to generic competition.
What generic launch scenarios exist after patent expiration?
Scenario 1: Full-label generic entry
A generic manufacturer launches ivacaftor after expiration with an FDA-approved label covering the relevant cystic fibrosis indications. This is the cleanest entry route.
Scenario 2: Earlier section viii entry
The applicant omits the patented G551D use while retaining non-patented uses. This can permit earlier approval, but the commercial label may be narrower and litigation risk may remain.
Scenario 3: Paragraph IV litigation
The applicant certifies that the patent is invalid, unenforceable, or not infringed. Vertex could file an infringement action, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework.[4]
Scenario 4: Authorized generic or settlement entry
Vertex could license an applicant or authorize generic distribution before patent expiry. No public settlement specific to this patent is identified in the cited records.
What revenue is exposed to this patent?
Kalydeco generated approximately $1 billion in annual product revenue for Vertex in the 2023 reporting period.[5] The patent does not cover all Vertex cystic fibrosis revenue. Its direct exposure is concentrated in:
- Kalydeco monotherapy;
- Patients with G551D and related approved ivacaftor-responsive populations;
- Revenue generated by the patented treatment method before May 2027.
Trikafta, Symdeko, and other combination products have distinct patent estates and materially broader commercial populations. Generic entry against Kalydeco alone would therefore have a smaller financial impact than entry against Vertex's combination-modulator franchise.
Key Takeaways
- U.S. Patent 8,324,242 is a method-of-treatment patent for ivacaftor in cystic fibrosis.
- Claim 1 is broadly directed to treating or lessening cystic fibrosis severity with an effective amount of ivacaftor.
- Claim 2 limits treatment to patients with a G551D CFTR mutation.
- Claims 3 and 4 separately cover homozygous and heterozygous G551D patients.
- The patent does not claim ivacaftor as a molecule or require a specific dosage form.
- The patent is listed in the FDA Orange Book for Kalydeco.
- The listed expiration date is May 24, 2027.
- A generic applicant could pursue Paragraph IV litigation, a section viii carveout, or post-expiration entry.
- The patent is one component of a broader Vertex estate covering ivacaftor compounds, formulations, combinations, and additional CFTR mutations.
- Kalydeco revenue exposure is material but substantially smaller than the exposure associated with Vertex's newer combination products.
FAQs About U.S. Patent 8,324,242
Does U.S. Patent 8,324,242 cover all uses of ivacaftor?
No. It covers specified methods of treating cystic fibrosis by administering ivacaftor. It does not claim every possible use of ivacaftor, nor does it claim the compound itself.
Does the patent cover patients with mutations other than G551D?
Claim 1 is not expressly limited to G551D. Claims 2 through 4 are limited to G551D. The enforceable scope of claim 1 would depend on claim construction and validity analysis.
Can a generic manufacturer launch ivacaftor before May 2027?
Potentially, through a successful Paragraph IV challenge, a valid section viii carveout, a license, or another legally permitted pathway. A full-label launch before patent expiration would create substantial infringement risk.
Is Kalydeco a biologic subject to biosimilar competition?
No. Ivacaftor is a chemically synthesized small molecule. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway under the Public Health Service Act.
Are Trikafta patents covered by U.S. Patent 8,324,242?
No. Trikafta is a combination of elexacaftor, tezacaftor, and ivacaftor. Its patents include separate claims directed to the combination, components, formulations, and treatment methods.
References
-
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,324,242, Methods of treating cystic fibrosis. U.S. Department of Commerce.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2012, January 31). FDA approves Kalydeco to treat rare form of cystic fibrosis. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements. U.S. Department of Health and Human Services.
-
Vertex Pharmaceuticals Incorporated. (2024). 2023 annual report. Vertex Pharmaceuticals Incorporated.
